Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Zalak Shah, Danielle Boselli, Stephanie Begley, Rupali Bose, Yifan Pang, Srinivasa Reddy Sanikommu, Nilay A. Shah, Aleksander L. Chojecki, Thomas G. Knight, Jing Ai, Belinda Avalos, Edward A. Copelan, Michael R. Grunwald, Brittany Knick Ragon

Blood (2024) 144 (Supplement 1): 5194.

https://doi.org/10.1182/blood-2024-201054

Published: 2024

Journal Articles

PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601

Steven I. Park, Stephen M. Ansell, Danielle Boselli, Sharmila Giri, Jakub Svoboda, Stephen D Smith, Tatyana Feldman, L. Elizabeth Budde, Andrew J Ness, Philip Bierman, Hun Ju Lee

Blood (2024) 144 (Supplement 1): 458.

https://doi.org/10.1182/blood-2024-202207

Published: 2024

Journal Articles

Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia

Thomas G. Knight, Danielle Boselli, Allison Verbyla, Jing Ai, Aleksander L. Chojecki, Nilay Shah, Yifan Pang, Lawrence J. Druhan, Edward A. Copelan, Michael R. Grunwald, Brittany Knick Ragon

Blood (2023) 142 (Supplement 1): 5078.

https://doi.org/10.1182/blood-2023-182371

Published: 2023

Journal Articles

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma

Steven I. Park, Lakshmi Nayak, Danielle Boselli, Raphael E Steiner, Ashley L Sumrall, Nazanin K Majd, Xhevahire Begic, Sarah Norek, Christopher Dittus

Blood (2023) 142 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2023-179526

Published: 2023

Journal Articles

Socioeconomic Disadvantage Is Associated with Decreased Long-Term Survival in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia

Allison Verbyla, Danielle Boselli, Brittany Knick Ragon, Jing Ai, Lawrence J. Druhan, Meng-Yun Lin, Michael R. Grunwald, Amresh Hanchate, Thomas G. Knight

Blood (2023) 142 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2023-182299

Published: 2023

Journal Articles

Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay Shah, Aleksander L. Chojecki, Srinivasa Reddy Sanikommu, Yifan Pang, Jing Ai, Belinda Avalos, Edward A. Copelan, Thomas G. Knight, Michael R. Grunwald

Blood (2023) 142 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2023-179352

Published: 2023

Journal Articles

Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience

Rushil V. Patel, Danielle Boselli, Patrick L Meadors, Stephanie Begley, Rupali Bose, Jing Ai, Brittany Knick Ragon, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Thomas G. Knight, James T. Symanowski, Declan Walsh, Michael R. Grunwald, Aleksander L. Chojecki

Blood (2022) 140 (Supplement 1): 5279–5280.

https://doi.org/10.1182/blood-2022-156494

Published: 2022

Journal Articles

Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay A. Shah, Aleksander L. Chojecki, Srinivasa Reddy R. Sanikommu, Jing Ai, Lawrence J Druhan, Nury M Steuerwald, Jai N Patel, James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Derek Raghavan, Thomas G. Knight, Michael R. Grunwald

Blood (2022) 140 (Supplement 1): 10993–10995.

https://doi.org/10.1182/blood-2022-159179

Published: 2022

Journal Articles

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Aleksander L. Chojecki, Justin Arnall, Danielle Boselli, Kristyn Y. DiSogra, Allison Karabinos, Tommy Chen, Jing Ai, Thomas G. Knight, Brittany Knick Ragon, Nilay A. Shah, Srinivasa R. Sanikommu, James T Symanowski, Belinda R Avalos, Edward A. Copelan, Michael R. Grunwald

Blood (2021) 138 (Supplement 1): 1252.

https://doi.org/10.1182/blood-2021-149811

Published: 2021

Journal Articles

Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Ashley Matuszfisher, Rupali Bose, Danielle Boselli, Gray Magee, Tommy Chen, Bei Hu, Tamara K. Moyo, Amy Soni, Steven I. Park, Edward A. Copelan, Belinda Avalos, James T Symanowski, Derek Raghavan, Ryan Jacobs, Nilanjan Ghosh

Blood (2021) 138 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2021-145714

Published: 2021

Journal Articles

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Bei Hu, MD, Tommy Chen, Danielle Boselli, MS, Rupali Bose, MS, MBA, James T. Symanowski, PhD, Derek Raghavan, MDPhDFACP,FRACP, Amy Soni, MD, Steven I Park, MD, Belinda R Avalos, MD, Edward A Copelan, Ryan Jacobs, MD, Nilanjan Ghosh, MD PhD

Blood (2019) 134 (Supplement_1): 425.

https://doi.org/10.1182/blood-2019-123998

Published: 2019

Journal Articles

Survival and Time to Response with Frontline Hypomethylating Agents in AML

Jing Ai, MD, Danielle Boselli, MS, Lauren M. Bohannon, Thomas G. Knight, MD, Brittany Ragon, MD, Belinda Rene Avalos, MD, Edward A. Copelan, MD, James T Symanowski, PhD, Jonathan M. Gerber, MD, Michael R. Grunwald, MD

Blood (2018) 132 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2018-99-119463

Published: 2018

Journal Articles

AcDVP16 Induction Therapy for Acute Myeloid Leukemia

Michael Richard Grunwald, MD, Amy M. Ellenburg, PharmD, Michael Keith Allister Zimmerman, MS, Jing Ai, MD PhD, Thomas G. Knight, MD, Lauren M. Bohannon, Danielle Boselli, MS, Jigar Trivedi, MSc, PharmD, Margaret A. Croom, PharmD, William E. Anderson, JD, MS, James T Symanowski, PhD, Edward A Copelan, MD, Dragos Plesca, PharmD, Jonathan M. Gerber, MD

Blood (2017) 130 (Supplement 1): 3902.

https://doi.org/10.1182/blood.V130.Suppl_1.3902.3902

Published: 2017

Journal Articles

Frontline Azacitidine As a Bridge to Allogeneic Transplantation in Acute Myeloid Leukemia

Michael Richard Grunwald, MD, Michael Keith Allister Zimmerman, MS, Danielle Boselli, MS, Lauren M. Bohannon, Myra M Robinson, MSPH, Daniel T. Peters, Jing Ai, MD PhD, Thomas G. Knight, MD, Jigar Trivedi, MSc, PharmD, Dragos Plesca, PharmD, James T Symanowski, PhD, Edward A Copelan, MD, Jonathan M. Gerber, MD

Blood (2017) 130 (Supplement 1): 3864.

https://doi.org/10.1182/blood.V130.Suppl_1.3864.3864

Published: 2017

NARROW

Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601

Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma

Socioeconomic Disadvantage Is Associated with Decreased Long-Term Survival in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia

Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience

Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Survival and Time to Response with Frontline Hypomethylating Agents in AML

AcDVP16 Induction Therapy for Acute Myeloid Leukemia

Frontline Azacitidine As a Bridge to Allogeneic Transplantation in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only